New Managed Markets E-Learning Courses From Pharmaceutical Institute Offer a Complete Public Payer Perspective

RALEIGH, N.C., Aug. 9, 2012 /PRNewswire/ -- Pharmaceutical Institute, the leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, has announced the availability of five new and updated e-courses designed to train managed markets and sales professionals on the inner-workings of US government health systems and programs.

Part of the Managed Markets Excellence® series, this public-sector-focused collection includes the following interactive e-courses:

• Federal Markets: Department of Defense and TRICARE (NEW)
• Federal Markets: Veterans Affairs (NEW)
• Medicare Part B (NEW)
• Medicare (Updated)
• Medicaid (Updated)

While the three e-courses covering the Federal Markets and Medicare Part B are new, the Medicare and Medicaid e-courses have been updated to reflect changes in the current managed markets environment—including the impact of the Affordable Care Act. They have also been redesigned to deliver highly interactive learning experiences via most electronic and mobile devices.

According to Garry O'Grady, Senior Vice President and General Manager of Pharmaceutical Institute, working successfully with public payers requires a unique knowledge base. "Public markets differ from the commercial sector in many ways," he said. "Through these courses, pharmaceutical companies can effectively teach their managed markets and sales teams the ins and outs of how government systems operate."

Each of these interactive courses, along with 40 new and updated courses in the Managed Markets Excellence® series, is available for electronic tablet, smart phone, and other handheld mobile devices—whether PC or Mac—including Apple iPad.

For a complete list of Managed Markets Excellence® courses, download the series brochure at http://www.pharmainstitute.com/userfiles/File/Managed-Markets-Brochure.pdf.

For more information about these courses, Pharmaceutical Institute's mobile learning capabilities, or custom course development, contact Pharmaceutical Institute at www.pharmainstitute.com/contact.

About Pharmaceutical Institute
Pharmaceutical Institute is the leading provider of specialized training programs for the pharmaceutical and biotech industry. We partner with subject matter experts from our parent company, Campbell Alliance, to develop high-impact distance learning solutions for professionals within all major pharmaceutical company functions including brand management, business development, clinical development, managed markets, medical affairs, sales, and trade and distribution.  Pharmaceutical Institute is based in Raleigh, NC. For more information, please visit http://www.pharmainstitute.com.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is an industry leader in biopharmaceutical and medical technology consulting. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Clinical Development, Commercial Effectiveness, Corporate Development, Medical Affairs, and Pricing and Market Access. From its locations in New York City; Raleigh, NC; Parsippany, NJ; Somerset, NJ; Newtown, PA; Los Angeles; San Francisco; Chicago; Boston; Philadelphia; London; and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech, and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners, and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced  and future acquisitions; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

SOURCE Pharmaceutical Institute